{"organizations": [], "uuid": "812eb4c48626309dfb2f099ef96c9d857b31cddb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merus-provides-clinical-updates-fo/brief-merus-provides-clinical-updates-for-mcla-117-and-mcla-158-programs-idUSASB0BZPX", "country": "US", "domain_rank": 408, "title": "BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:06:00.000+02:00", "replies_count": 0, "uuid": "812eb4c48626309dfb2f099ef96c9d857b31cddb"}, "author": "", "url": "https://www.reuters.com/article/brief-merus-provides-clinical-updates-fo/brief-merus-provides-clinical-updates-for-mcla-117-and-mcla-158-programs-idUSASB0BZPX", "ord_in_thread": 0, "title": "BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "belgium", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "merus nv", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 07 PM / Updated 9 minutes ago BRIEF-Merus Provides Clinical Updates For Mcla-117 And Mcla-158 Programs Reuters Staff \nJan 4 (Reuters) - Merus Nv: \n* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS \n* MERUS NV - PLANS TO FILE AN IND FOR MCLA-158 WITH U.S. FDA IN Q1 OF 2018​ \n* MERUS NV - APPROVAL OF CLINICAL TRIAL APPLICATION IN BELGIUM, WHERE IT PLANS TO FIRST INITIATE PHASE 1, FIRST-IN-HUMAN CLINICAL TRIAL OF MCLA-158​ Source text for Eikon:  ", "external_links": [], "published": "2018-01-04T14:06:00.000+02:00", "crawled": "2018-01-04T14:27:10.061+02:00", "highlightTitle": ""}